Business
Hemab Therapeutics Expands Leadership with Appointment of Anant Murthy, PhD, as Chief Operating Officer
Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today announced the appointment of Anant Murthy, PhD, as Chief Operating Officer. In this new role, Murthy will lead the company's global efforts in market access, launch, and commercialization, bringing Hemab's promising pipeline of treatments for Glanzmann thrombasthenia (GT), Von Willebrand disease (VWD), and other neglected blood cl
About this update from Alnylam Pharmaceuticals, Inc.
[{"type":"text","content":"Seasoned global market access and commercialization expert brings demonstrated track record of successful specialty medicine launches to support Hemab's multiple clinical programs in high unmet need diseases","length":216,"tagName":"p","attribs":{}},{"type":"text","content":"COPENHAGEN, Denmark and CAMBRIDGE, Mass., Sept. 2, 2025 /PRNewswire/ -- Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today announced the appointment of Anant Murthy, PhD, as Chief Operating Officer. In this new role, Murthy will lead the company's global efforts in market access, launch, and commercialization, bringing Hemab's promising pipeline of treatments for Glanzmann thrombasthenia (GT), Von Willebrand disease (VWD), and other neglected blood clotting disorders with high unmet needs to patients worldwide.","length":641,"tagName":"p"},{"type":"image","alt":"Hemab Therapeutics (PRNewsfoto/Hemab Therapeutics)","displaySize":"","headline":null,"caption":"Hemab Therapeutics (PRNewsfoto/Hemab Therapeutics)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":90,"url":"https://media.zenfs.com/en/prnewswire.com/4c5c0dab48a1cf84fcbbb57c7592d032"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/njQa1ze0y7tkgHw4w_EssQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE1OTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/4c5c0dab48a1cf84fcbbb57c7592d032","width":400,"height":90}},"href":"https://mma.prnewswire.com/media/1719756/Hemab_Therapeutics_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Anant brings a wealth of unique experience in delivering specialized medicines to patients facing significant health challenges. His prior experience as EMEA General Manager at argenx, Vice President at Alnylam Pharmaceuticals, and multiple senior leadership roles at ARIAD Pharmaceuticals and Celgene Corporation, among others, have equipped him with the expertise and demonstrated track record required to navigate the complexities of developing and delivering innovative therapies to those in need.","length":501,"tagName":"p"},{"type":"text","content":""We are thrilled to welcome Anant as our COO. His extensive experience, coupled with his creative and innovative thinking, makes him the pe...